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the atorvastatin metabolic 
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interaction of drug-transporter 
polymorphisms in Mexican 
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trial
Rafael B. R. León-Cachón1 ✉, Aileen-Diane Bamford1, irene Meester1,  
Hugo Alberto Barrera-Saldaña2,3, Magdalena Gómez-Silva4,5 & María f. García Bustos6,7
Atorvastatin (ATV) is a blood cholesterol-lowering drug used to prevent cardiovascular events, the 
leading cause of death worldwide. As pharmacokinetics, metabolism and response vary among 
individuals, we wanted to determine the most reliable metabolic ATV phenotypes and identify novel 
and preponderant genetic markers that affect ATV plasma levels. A controlled, randomized, crossover, 
single-blind, three-treatment, three-period, and six-sequence clinical study of ATV (single 80-mg oral 
dose) was conducted among 60 healthy Mexican men. ATV plasma levels were measured using high-
performance liquid chromatography mass spectrometry. Genotyping was performed by real-time 
PCR with TaqMan probes. Four ATV metabolizer phenotypes were found: slow, intermediate, normal 
and fast. Six gene polymorphisms, SLCO1B1-rs4149056, ABCB1-rs1045642, CYP2D6-rs1135840, 
CYP2B6-rs3745274, NAT2-rs1208, and COMT- rs4680, had a significant effect on ATV pharmacokinetics 
(P < 0.05). The polymorphisms in SLCO1B1 and ABCB1 seemed to have a greater effect and were 
especially important for the shift from an intermediate to a normal metabolizer. This is the first study 
that demonstrates how the interaction of genetic variants affect metabolic phenotyping and improves 
understanding of how SLCO1B1 and ABCB1 variants that affect statin metabolism may partially explain 
the variability in drug response. Notwithstanding, the influence of other genetic and non-genetic 
factors is not ruled out.
Cardiovascular diseases (CVD) are the leading cause of death worldwide1 and in Mexico2. Diet, a lack of physical 
activity, and ageing are risk factors for CVD, but smoking, a high blood pressure and a high blood cholesterol 
level are at the top3. Statins are the first-choice drugs to treat hypercholesterolemia, and atorvastatin (ATV) is 
one of the most used statins4,5. However, interindividual variability in both ATV metabolism6–8 and therapeutic 
response9–11 have been reported. Three ATV metabolic phenotypes have been identified6,8,12 and non-validated 
massive genotyping methods identified genetic variants that seemed to impact ATV pharmacokinetics6,13.
The classification of metabolic phenotypes is challenging because of large datasets, variables at different scales, 
and limited knowledge on phenotyping data management14. Gene expression studies on large data sets of tissue 
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samples15 and patients16 often apply cluster analysis, but its use is uncommon in pharmacogenomics and pharma-
cogenetics6,17. Cluster analysis of pharmacogenetics data could facilitate the screening for possible pharmacoki-
netic and metabolic profiles if the optimal number of groups and cut-off limits can be defined.
Several genes have been related to the variability in statin metabolism and response. Hepatic uptake and clear-
ance largely depend on influx and efflux transporters such as those encoded by the genes ABCB1 and SLCO1B17,18. 
In biotransformation, genes encoding phase I metabolic enzymes, such as CYP3A4, CYP3A5, CYP2D6, and 
CYP2B6, are relevant, because they metabolize many drugs. Although it is known that CYP3A4 and CYP3A5 
metabolize statins, the polymorphisms CYP3A4-rs2740574 and CYP3A5-rs776746 occurred at a low frequency 
in the Mexican population and no effect on ATV metabolism was detected. The contribution of CYP2D6 variants 
could not be tested due to a low call rate of the genotyping method. A potential effect of CYP2B6 has not been 
confirmed. Likewise, the effect on ATV metabolism could not be proven for variants of genes encoding phase II 
metabolic enzymes (NAT2 and COMT) for the same reasons6,13,19. In this study among a Mexican population, we 
applied a novel approach to identify and confirm ATV metabolic phenotypes and associated pharmacogenetic 
profiles. Hereto, we selected candidate genes involved in the metabolism and response to drugs, i.e. ABCB1, 
SLCO1B1 and CYP2D6, based on previous reports, frequency, and importance in the Mexican population and 
analyzed them under genetic models to identify or confirm their effect on the pharmacokinetics of ATV.
Results
Study population. All participants were healthy non-related male Mexicans who identified themselves as 
mestizos. Most (93.1%) were residents from northeastern Mexican states, namely Nuevo Leon (83.3%), Coahuila 
(1.6%), Tamaulipas (3.3%) and San Luis Potosi (4.9%). The volunteers had similar anthropometric data, and no 
significant differences in body composition. No adverse effects due to drug administration occurred6.
Pharmacokinetic analysis. Under controlled conditions, the mean ± standard deviation (SD) of 
adjusted pharmacokinetic parameters used for phenotyping were: maximum plasma concentration (Cmax) = 
41.70 ± 21.51 ng/mL, the area under the plasma ATV concentration-time curve (AUC) from time 0 to the time 
of last measurement (AUC0-t) = 143.35 ± 84.64 ng/mL*h, AUC from time 0 extrapolated to infinity (AUC0-
∞) = 155.84 ± 85.79 ng/mL*h, and the total drug clearance (Cl) = 0.65 ± 0.31 L/h*kg (Table 1). The coefficient of 
variation (CV) was greater than 50% for all parameters, except for Cl, which was 48%.
ATV metabolizer phenotypes. Cluster analysis distinguished four clusters or phenotypes that most reli-
ably explained the observed pharmacokinetic variability (Table 1). When we applied this algorithm, the adjusted 
R-square for Cmax was 0.519; for AUC0-t, 0.865; for AUC0-∞, 0.866; and for Cl, 0.783 (P < 0.05). The defined phe-
notypes were: slow metabolizers (n = 3), intermediate metabolizers (n = 15), normal metabolizers (n = 28) and 
fast metabolizers (n = 14) as shown in Fig. 1a. Aforementioned pharmacokinetic parameters were significantly 
different (P < 0.05) among the metabolizer phenotypes, except for the Cmax values between intermediate and 
normal metabolizers (P = 0.09). Mean ATV pharmacokinetic parameters differed more than 10-fold between 
the fastest and slowest metabolizer groups (Cmax = 8.80 ng/mL, AUC0-t = 38.42 ng/mL*h, AUC0-∞ = 46.92 ng/
mL*h, Cl = 1.71 L/h*kg vs. Cmax = 89.86 ng/mL, AUC0-t = 467.93 ng/mL*h, AUC0-∞ = 477.81 ng/mL*h and Cl = 
0.17 L/h*kg; respectively).
Pharmacogenetic tests. The call rate for the seven gene polymorphisms was 1.0. All genetic markers were 
in Hardy-Weinberg Equilibrium (P > 0.05) and had a minor allele frequency > 0.01. The haplotype analysis 
revealed that the most frequent haplotypes were CTTT (n = 26; 43%) CCTT (n = 12; 20%) and TTTT (n = 11; 
18%), result of the combination of ABCB1-rs1045642 and SLCO1B1-rs4149056 polymorphisms.
Effect of gene polymorphisms and haplotypes on atorvastatin pharmacokinetics. Five gene 
polymorphisms had a significant effect on different pharmacokinetic parameters. Cmax values were influenced 
by ABCB1-rs1045642 polymorphism under a dominant model. C/C carriers had a significant lower Cmax 
(P = 0.038) than C/T and T/T carriers (Table 2). With respect to SLCO1B1-rs4149056, C carriers (homozy-
gous or heterozygous) had a higher AUC0-t, AUC0-∞, Cl and volume of distribution (Vd) than the homozygous 
T genotype (P ≤ 0.038; Table 2). Regarding the metabolizer enzyme variants, heterozygous carriers (C/G) of 
CYP2D6-rs1135840 had higher elimination rate constant in the terminal drug phase (Ke) values, but significantly 
lower half-life (T1/2) values than those with homozygous genotypes (P ≤ 0.022; Table 2). Similarly, COMT-rs4680 
G/G carriers had a higher AUC0-∞, but lower Cl than A/A and A/G carriers (P ≤ 0.048; Table 2). We also found 
a significant effect of the CCTT haplotype (of the combination of ABCB1 and SLCO1B1 drug transporters) on 
Cmax, AUC0-t, AUC0-∞ and Cl parameters (P ≤ 0.040). Subjects with a CCTT genetic profile in drug transporter 
genes had lower Cmax, AUC0-t, and AUC0-∞, but a higher Cl than those with other combinations (Table 2). The 
regression analysis confirmed that three gene polymorphisms (ABCB1-rs1045642, SLCO1B1-rs4149056 and 
COMT-rs4680) had an impact on ATV pharmacokinetics (Table 3). The regression analysis also revealed that 
CYP2B6-rs3745274 and NAT2-rs1208 are involved in pharmacokinetic variability. The CYP2B6-rs3745274 pol-
ymorphisms influenced the variability of Cmax (in the over-dominant model; Table 3) and NAT2-rs1208 variants 
affect AUC0-∞ (under the co-dominant and dominant models; Table 3). No other polymorphisms had a signifi-
cant effect on ATV pharmacokinetics.
Interaction of gene polymorphism on atorvastatin pharmacokinetics. The interaction of 
ABCB1-rs1045642 with CYP2B6-rs3745274, under the dominant and over-dominant model, respectively, pre-
dicted 11.1% of the Cmax variability (Table 3). Furthermore, under the co-dominant model, the interaction of 
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SLCO1B1-rs4149056 with NAT2-rs1208 predicted 19.7% of the AUC0-∞ variation. In another approach to test 
gene polymorphism interactions, after a genotype adjustment of intermediate metabolizers, i.e. three subjects 
with a C/C genotype for ABCB1-rs1045642 were removed from the group, the normal and intermediate metabo-
lizers became significantly different (Fig. 1b). The new mean ± SD for Cmax of intermediate metabolizers became 
59.23 ± 20.12 ng/mL (cut-off 46.45–72.02 ng/mL) and the adjusted R-square increased to 0.700 (P < 0.005). In 
addition, CCTT carriers were only ones that were statistically different from other subjects (Table 4).
Phenotype-genotype association. When the association between phenotypes and genotypes was 
assessed, we found that, under the recessive model, SLCO1B1-rs4149056 is associated with fast/normal metab-
olizers while the presence of allele C is related to slow/intermediate metabolizers (Table 5). This association 
Figure 1. Mean peak plasma ATV concentration-time curves, according to phenotypes and genotypes. 
(a) Pharmacokinetic profiles of different metabolic phenotypes. (b) Pharmacokinetic profiles of different 
metabolic phenotypes with ABCB1-rs1045642 genotype C/C adjusting. For both (a,b): slow metabolizers 
(red), intermediate metabolizers (orange), normal metabolizers (green) and fast metabolizers (blue). (c) 
Pharmacokinetic profiles of ABCB1-rs1045642 genotypes: carriers of C/C genotype (blue) and carriers of C/T 
or T/T genotypes (orange) (d) Pharmacokinetic profiles of SLCO1B1-rs4149056 genotypes: carriers of C/C or 
C/T genotype (blue) and carriers of T/T genotypes (orange). Mean peak plasma concentration-time curves after 
single 80-mg dose of ATV. Data shown are mean ± standard error (SE) concentrations.
Phenotypes n
Pharmacokinetic parameters
Cmax (ng/ml)a AUC0-t (ng/ml*h)b AUC0-∞ (ng/ml*h)b Cl (L/h*kg)b
Slow 3
87.05 ± 3.29 411.91 ± 49.18 421.06 ± 49.24 0.19 ± 0.02
(78.88-95.22) (289.74–534.07) (298.73–543.38) (0.14–0.25)
Intermediate 15
54.50 ± 20.40 206.49 ± 45.95 223.19 ± 48.57 0.37 ± 0.07
(43.20–65.79) (181.04–231.94) (196.29–250.08) (0.33–0.41)
Normal 28
39.20 ± 13.46 119.73 ± 17.41 130.94 ± 18.59 0.62 ± 0.09
(33.98–44.42) (112.98–126.48) (123.73–138.15) (0.59–0.66)
Fast 14
21.95 ± 9.00 65.37 ± 15.52 76.66 ± 14.7 1.09 ± 0.26
(16.76–27.15) (56.41–74.33) (68.17–85.15) (0.94–1.24)
All subjects 60 41.70 ± 21.51 143.35 ± 84.64 155.84 ± 85.79 0.65 ± 0.31
Table 1. Pharmacokinetic parameters and cut-off according to metabolizer phenotype. Data shown as mean ± 
standard deviation, cut-off limits in parenthesis. aP ≤ 1.6×10–4 for comparison between all phenotypes, except 
intermediate vs. normal (P = 0.094); bP ≤ 0.002 for comparison between all phenotypes. Cmax, maximum 
plasma concentration; AUC, area under the plasma concentration-time curve; AUC0-t, AUC from time 0 to the 
time of last measurement; AUC0- ∞ , AUC from time 0 extrapolated to infinity; Cl, total clearance.
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remained after Bonferroni correction and was supported by logistic regression (P = 0.002). No association was 
found between other haplotypes and phenotypes.
Discussion
Despite similar health conditions, body composition, and controlled experimental conditions, ATV pharmacoki-
netic parameters varied greatly among Mexican male individuals. We applied a novel approach (cluster analysis 
based on more pharmacokinetic parameters than a previous method) that distinguished four metabolizer phe-
notypes with higher accuracy and reliability than a previously reported classification method6. Furthermore, it 
allowed the selection of a model with the highest prediction percentage and best cut-off limits for each metab-
olizer phenotype. In addition, the analysis allowed identifying inconsistencies. For example, after phenotyping, 
considerable variability of Cmax values was observed in the intermediate metabolizer group, suggesting that there 
are important differences between individuals in the absorption process.
Although the clustering analysis method has been successfully applied for classification purposes in other 
areas of biomedical research14–16, it has been little used in pharmacokinetics, pharmacogenetics and pharma-
cogenomics6. A reason might be the need to realize multiple analyzes to select the ideal number of clusters. In 
our experience, the cluster analysis method proved to be a) effective in identifying the different groups within a 




ml*h) Ke T1/2 (h) Cl (L/h*kg) Vd (L/kg)
ABCB1-rs1045642
C/C 14 31.22 ± 15.38 115.33 ± 64.68 127.6 ± 65.25 0.0871 ± 0.0488 10.33 ± 5.20 0.81 ± 0.45 10.61 ± 4.68
C/T 32 45.76 ± 21.51 159.45 ± 100.64 173.28 ± 102.13 0.0760 ± 0.0290 11.62 ± 7.69 0.59 ± 0.26 9.2 ± 5.77
T/T 14 41.59 ± 22.49 134.56 ± 51.09 144.22 ± 50.17 0.0759 ± 0.0314 10.94 ± 5.19 0.62 ± 0.20 9.39 ± 4.70
C/T + T/T 46 44.49 ± 21.64a 151.87 ± 88.69 164.44 ± 89.97 0.0760 ± 0.0294 11.41 ± 6.98 0.60 ± 0.24 9.26 ± 5.42
SLCO1B1-rs4149056
C/C 1 47.00 ± N.A. 198.79 ± N.A. 288.28 ± N.A. 0.0190 ± N.A. 36.43 ± N.A. 0.28 ± N.A. 14.58 ± N.A.
C/T 10 50.90 ± 27.37 210.16 ± 112.11 220.93 ± 112.54 0.0774 ± 0.0294 10.02 ± 3.40 0.45 ± 0.22 5.90 ± 2.20
T/T 49 39.34 ± 19.45 128.58 ± 72.33 139.86 ± 71.85 0.08000 ± 0.0353 10.88 ± 6.11 0.70 ± 0.31 10.22 ± 5.40
C/C + C/T 11 50.55 ± 25.99 209.13 ± 106.41b 227.05 ± 108.68c 0.0721 ± 0.0330 12.42 ± 8.59 0.43 ± 0.21d 6.68 ± 3.35e
CYP2B6-rs3745274
G/G 36 46.30 ± 23.54 156.06 ± 99.43 167.17 ± 98.65 0.0808 ± 0.0355 10.42 ± 5.29 0.62 ± 0.29 8.82 ± 5.08
G/T 22 33.72 ± 14.57 123.39 ± 52.47 138.82 ± 60.93 0.0732 ± 0.0349 12.75 ± 8.35 0.70 ± 0.36 11.08 ± 5.46
T/T 2 37.39 ± 0.18 133.99 ± 63.54 139.23 ± 63.96 0.0982 ± 0.0059 7.07 ± 0.42 0.64 ± 0.30 6.46 ± 2.62
G/G + T/T 38 45.83 ± 22.98 154.9 ± 97.40 165.7 ± 96.73 0.0817 ± 0.0348 10.24 ± 5.20 0.62 ± 0.28 8.70 ± 4.99
CYP2D6-rs16947
A/A 3 35.31 ± 10.03 135.17 ± 40.13 155.20 ± 26.99 0.0582 ± 0.0335 15.21 ± 9.12 0.52 ± 0.09 12.28 ± 8.99
A/G 24 42.80 ± 24.14 133.18 ± 88.41 145.03 ± 87.42 0.0859 ± 0.0413 10.64 ± 6.96 0.72 ± 0.38 10.27 ± 6.35
G/G 33 40.92 ± 19.59 151.48 ± 85.65 163.76 ± 88.76 0.0751 ± 0.0290 11.18 ± 6.17 0.61 ± 0.27 8.82 ± 3.88
A/A + G/G 36 40.45 ± 18.95 150.13 ± 82.59 163.05 ± 85.15 0.0737 ± 0.0292 11.51 ± 6.39 0.60 ± 0.26 9.11 ± 4.40
CYP2D6-rs1135840
C/C 25 42.15 ± 20.49 155.64 ± 90.39 169.10 ± 94.13 0.0714 ± 0.0300 11.97 ± 6.74 0.60 ± 0.27 9.22 ± 4.19
C/G 28 39.65 ± 21.74 126.68 ± 74.86 137.21 ± 73.28 0.0896 ± 0.0376 9.55 ± 5.52 0.73 ± 0.35 9.41 ± 5.46
G/G 7 45.65 ± 22.29 166.11 ± 100.07 183.04 ± 97.68 0.0600 ± 0.0268 14.74 ± 8.77 0.53 ± 0.23 11.48 ± 7.86
C/C + G/G 32 42.91 ± 20.58 157.93 ± 91.01 172.15 ± 93.49 0.0689 ± 0.0293f 12.57 ± 7.17g 0.58 ± 0.26 9.72 ± 5.14
NAT2-rs1208
A/A 25 46.39 ± 22.25 156.10 ± 110.43 171.21 ± 112.16 0.0827 ± 0.0444 11.98 ± 8.53 0.64 ± 0.35 9.76 ± 5.91
A/G 28 37.81 ± 19.58 135.79 ± 64.94 146.88 ± 64.75 0.0741 ± 0.0235 10.70 ± 4.94 0.66 ± 0.31 9.69 ± 5.24
G/G 7 37.89 ± 21.38 128.01 ± 38.24 136.80 ± 37.38 0.0818 ± 0.0365 10.08 ± 4.45 0.63 ± 0.19 8.41 ± 2.49
A/G + G/G 35 37.82 ± 19.62 134.24 ± 60.14 144.87 ± 59.94 0.0756 ± 0.0261 10.58 ± 4.79 0.65 ± 0.29 9.44 ± 4.81
COMT-rs4680
A/A 9 30.47 ± 9.09 107.08 ± 33.40 116.03 ± 36.04 0.0859 ± 0.0363 9.69 ± 4.59 0.74 ± 0.20 9.60 ± 3.37
A/G 29 39.67 ± 21.27 139.81 ± 93.84 152.93 ± 96.83 0.0794 ± 0.0293 10.93 ± 7.04 0.69 ± 0.36 9.71 ± 5.17
G/G 22 48.13 ± 22.42 162.85 ± 83.54 175.97 ± 81.02 0.0744 ± 0.0413 12.07 ± 6.76 0.55 ± 0.26 9.37 ± 6.11
A/A + A/G 38 37.49 ± 19.39 132.06 ± 84.29 144.19 ± 87.34h 0.0810 ± 0.0307 10.64 ± 6.51 0.70 ± 0.33i 9.69 ± 4.76
Table 2. Effect of gene variants on ATV pharmacokinetics. Data shown as mean ± standard deviation. 
aP = 0.038 (C/C vs. C/T + T/T); bP = 0.003 (T/T vs. C/C + C/T); cP = 0.004 (T/T vs. C/C + C/T); dP = 0.005 
(T/T vs. C/C + C/T); eP = 0.038; fP = 0.020 (C/G vs. C/C + G/G); gP = 0.022 (C/G vs. C/C + G/G); hP = 0.046 
(A/A + A/G vs. G/G); i P = 0.048 (A/A + A/G vs. G/G). Cmax, maximum plasma concentration; AUC, area 
under the plasma concentration-time curve; AUC0-t, AUC from time 0 to the time of last measurement; 
AUC0- ∞ , AUC from time 0 extrapolated to infinity; Ke, elimination rate constant in the terminal drug phase; 
T1/2, half-life drug; Cl, total clearance; Vd, volume of distribution. N.A., not apply.
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population, b) useful to determine which are the groups or subgroups that require more focus, and c) practical 
to evaluate the absorption, distribution, metabolism and excretion (ADME) process when no metabolic data are 
available, as only pharmacokinetic data are required.
The classification for this Mexican population should not be extrapolated indiscriminately to other 
populations, because population-specific intrinsic genetic variation may shift pharmacokinetics. Thus, 
population-specific ATV pharmacokinetic stratification criteria should be determined. Hereto, we recommend 
to develop an analogous cluster analysis which can be applied retrospectively. The pharmacokinetic variability of 
ATV observed in our population differed from the one reported for a Bengali population20. In both studies, the 
volunteers were young adult males, but the dose (40 vs. 80 mg) and race (Bengali vs. Mexican genetic background) 







ml*h) Ke T1/2 (h) Cl (L/h*kg) Vd (L/kg)
CTTT 26 44.95 ± 20.94 143.54 ± 88.13 154.99 ± 87.15 0.0785 ± 0.0286 10.97 ± 6.82 0.64 ± 0.26 9.70 ± 6.05
CCTT 12 30.63 ± 16.58a 97.58 ± 45.55b 110.08 ± 47.10c 0.0921 ± 0.0509 9.88 ± 5.33 0.89 ± 0.44d 11.18 ± 4.64
TTTT 11 35.57 ± 15.13 127.03 ± 40.91 136.57 ± 41.00 0.0704 ± 0.0284 11.74 ± 5.48 0.63 ± 0.18 10.39 ± 4.82
CTCT 5 49.74 ± 28.62 234.28 ± 144.62 245.40 ± 143.26 0.0745 ± 0.0235 10.02 ± 2.96 0.42 ± 0.20 5.49 ± 1.91
TTCT 3 63.63 ± 34.83 162.17 ± 84.53 172.25 ± 80.35 0.0960 ± 0.0402 8.02 ± 2.91 0.56 ± 0.32 5.73 ± 1.48
CCCT 2 34.71 ± 4.62 221.86 ± 71.26 232.78 ± 71.62 0.0569 ± 0.0205 13.03 ± 4.69 0.36 ± 0.11 7.15 ± 4.53
CTCC 1 47.00 ± N.A. 198 ± N.A. 288.28 ± N.A. 0.0190 ± N.A. 36.43 ± N.A. 0.28 ± N.A. 14.58 ± N.A.
Not-CCTT 48 44.08 ± 21.28 154.79 ± 88.53 167.28 ± 89.73 0.0752 ± 0.0292 11.48 ± 6.87 0.59 ± 0.24 9.17 ± 5.36
Table 3. Pharmacokinetic parameters of gene transporters haplotype. Data shown as mean ± standard 
deviation. aP = 0.040 (CCTT vs. Not-CCTT); bP = 0.028 (CCTT vs. Not-CCTT); cP = 0.037 (CCTT vs. Not-
CCTT); dP = 0.040 (CCTT vs. Not-CCTT). P values supported by linear, logistic and logarithmic regression 
analysis. Cmax, maximum plasma concentration; AUC, area under the plasma concentration-time curve; 
AUC0-t, AUC from time 0 to the time of last measurement; AUC0- ∞ , AUC from time 0 extrapolated to 
infinity; Ke, elimination rate constant in the terminal drug phase; T1/2, half-life drug; Cl, total clearance; Vd, 
volume of distribution. N.A., not apply.




1 rs4680 Co-dominant 0.083 0.067 0.026a
2 rs3745274 Over-dominant 0.079 0.063 0.030a
3 rs3745274, rs1045642 Over-dominant, dominant 0.141 0.111 0.046a
AUC0-t
1 rs4149056 Co-dominant 0.124 0.109 0.006a
2 rs4149056 Recessive 0.138 0.123 0.003a
AUC0-∞
1 rs4149056 Co-dominant 0.166 0.152 0.001a
2 rs4149056, rs1208 Co-dominant 0.225 0.197 0.043b
3 rs4149056 Recessive 0.157 0.143 0.002a
4 rs4149056, rs1208 Recessive, dominant 0.219 0.192 0.038b
Cl 1 rs4149056 Co-dominant 0.113 0.097 0.009a
Table 4. Gene predictors models of the pharmacokinetic parameters of atorvastatin. aP-value supported by 
logistic, logarithmic and linear regression analysis. b P-value supported by linear regression. Cmax, maximum 
plasma concentration; AUC, area under the plasma concentration-time curve; AUC0-t, AUC from time 0 to the 
time of last measurement; AUC0-∞, AUC from time 0 extrapolated to infinity; Cl, total clearance.
Gene Polymorphism Model OR (95% CI) P-Value Pc-Value








Table 5. Association between genotypes and metabolizer phenotypes. OR, odds ratio; CI, confidence interval; 
Pc, Bonferroni-corrected P-values. *Pc value supported by logistic regression.
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We assessed common genetic variants involved in drug metabolism to verify and confirm their influence on 
ATV pharmacokinetic variability. After genotyping validation, the genotype distribution of ABCB1-rs1045642 
(0.23 for C/C; 0.53 for C/T and 0.23 for T/T) differed from a previously reported distribution that had been 
obtained with microarrays6. Importantly, the effect on Cmax values remains significant. The ABCB1 gene encodes 
a transporter protein that has affinity for multiple substrates, both endogenous and exogenous ones21. The pol-
ymorphism rs1045642 is located in exon 26 and produces a synonymous substitution, so the role of the ABCB1 
variant in plasma drug concentrations is controversial22. Even so, rs1045642 variant may influence the folding 
time of the protein, alter its specificity, and therefore influence the concentration of a given drug23. In addition, 
synergistic or antagonistic interactions with other gene variants may create variability. So far, evidence on syn-
ergistic or antagonistic effect of ABCB1 on ATV plasma concentrations is scarce13.The significantly lower values 
in C/C carriers and the dominant effect of allele T suggest that the rs1045642 polymorphism significantly affects 
the absorption, bioavailability and blood concentrations of ATV. This hypothesis is supported by the intestinal 
expression of ABCB1, where this transporter actively participates in drug absorption24. These data on rs1045642 
are consistent with previous findings, even for different drugs and populations. T/T carriers had a higher Cmax 
for ATV among Americans and for rosuvastatin among Chinese, while C/C carriers had a lower Cmax and AUC 
for edoxaban and also in Mexicans for amfepramone17,18,25,26. Contrasting data, however, were found in a Korean 
population, where T/T carriers had a lower Cmax and longer half-life than C allele carriers. The group size was 
small (n = 3), though27. As far as we know, there is no other report about the effect of ABCB1-rs1045642 on the 
pharmacokinetics of other statins28,29. Our findings suggest that a lower concentration of drug may yield a lower 
response, whereas an increased exposure to the medicine could cause adverse effects. Conversely, the lack of phar-
macodynamic data did not allow us to evaluate the response to treatment and confirm our hypothesis. Despite 
this limitation, the association between ABCB1-rs1045642 and the pharmacological response to ATV has been 
well documented. For example, the C/C genotype among Australian patients treated with ATV associated with a 
lower treatment efficiency (i.e. less decrease in LDL values) as compared to other genotypes30. Similar data have 
been reported for Egyptian males9, Iranian31 and Polish populations32, and in a meta-analysis where 395 patients 
were included and treated with statins33. Regarding adverse effects, a higher frequency of the T allele has been 
found in patients who presented with myalgia, but no association has been reported30.
In our analysis, the genotype frequency of SLCO1B1-rs4149056 was similar to the one we have previously 
reported6. The new clustering analysis method confirmed the effect of SLCO1B1-rs4149056 on ATV pharma-
cokinetics. The SLCO1B1 gene codes for a protein responsible for the transport of organic anions and other 
compounds, such as drugs. This gene is expressed exclusively in the liver, where it has an important role in metab-
olism34. The rs4149056 polymorphism generates a p.V174A substitution that causes a decrease in expression 
and transport activity35. SLCO1B1-rs4149056 had the greatest effect on ATV pharmacokinetics. The presence 
of the C allele in SLCO1B1-rs4149056 seemed to affect AUC0-t, AUC0-∞, Cl, Vd, and therefore impact the expo-
sure to ATV, which was consistent with its occurrence in normal/faster phenotypes. The association between 
SLCO1B1-rs4149056 and aforementioned pharmacokinetic parameters indicates that the variant mainly affects 
the metabolism and excretion phases of ATV in the Mexican population as opposed to ABCB1-rs1045642, 
which apparently affects the absorption phase. This assumption is consistent with ATV pharmacokinetics in 
Chinese (n = 32), Japanese (n = 31), Caucasian (n = 30), and Korean (n = 28) populations where the presence of 
the C allele of polymorphism rs4149056 was associated with higher Cmax and/or AUC values7,27,36. In our study, 
rs4149056 has a preponderant role on ATV metabolism, since it was the only one that showed an association 
with metabolic phenotypes. Again, the higher AUC and slower clearance in C allele carriers could result in a 
better response or a higher susceptibility to adverse effects. The latter, may be explained by the statin response 
studies, where the C allele has been related to the risk of myopathy37,38. In all studies, the C/C genotype was the 
least frequent.
CYP2D6 codes for one of the main drug metabolizing enzymes, since it participates in the biotransforma-
tion of around 25% of all drugs39. The CYP2D6-rs1135840 polymorphism creates an alternative splicing site 
that eliminates exon 6, without a significant impact on gene expression40. Another CYP2D6 polymorphism, 
CYP2D6-rs3892097, has been associated with ATV-induced adverse effects on muscle41. However, there 
is little information about the role of CYP2D6 in ATV metabolism or pharmacokinetics. In a previous study, 
CYP2D6-rs1135840 seemed to have a significant effect on AUC values13, but this finding was not confirmed in 
this study. Here, we identified that CYP2D6-rs1135840 has a significant effect on Ke and T1/2 parameters, but this 
was not confirmed with the regression analyses, so its effect on the metabolism and excretion phases is not clear.
The catechol-O-methyltransferase, encoded by the COMT gene, is an enzyme that helps to eliminate endog-
enous or toxic metabolites, as well as exogenous polycyclic compounds42,43. Due to its regulatory function of cat-
echolamines, more is known about its role in pharmacodynamics than its role in pharmacokinetics44. The A allele 
related to susceptibility to coronary artery disease44. We discovered a significant effect of the COMT-rs4680 poly-
morphism on the Cmax, AUC0-∞ and Cl of ATV, although this effect was not supported by regression analysis. The 
rs4680 variant produces a non-synonymous amino acid change (p.V158M) causing impaired COMT activity44,45. 
As far as we know this is the first study that reports a possible effect of COMT-rs4680 on ATV pharmacokinetics.
CYP2B6 is a P450 family pharmacogene responsible for the metabolism of 4% of the main drugs19,46. The 
CYP2B6 gene is expressed primarily in the liver19,47 and its expression can be induced by different substrates 
including ATV48. The rs3745274 is located in exon 4 and produces a p.Q172H substitution, which is related with a 
slight reduction in expression and activity19. The T allele variant of rs3745274 has been related to a lower propofol 
dose49 and an increased exposure to efavirenz50. Although ATV induced CYP2B6 expression in cultured human 
hepatocytes51, the role of CYP2B6 on ATV pharmacokinetics in vivo is unknown. Our results show that, under 
an over-dominant model, rs3745274 affects the variation of Cmax, suggesting a slight role in ATV absorption of 
an unknown mechanism.
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The N-acetyltransferase 2 gene (NAT2) encodes a phase II metabolic enzyme involved in the biotransfor-
mation of drugs and carcinogens. NAT2 has many variations and has been associated with different metabolic 
phenotypes52, especially for anti-tuberculosis drugs53. The NAT2-rs1208 produces a p.K268R substitution that 
associates with a rapid acetylation52. To date, the influence of NAT2-rs1208 on statin pharmacokinetics has not 
been reported. We found that NAT2-rs1208 affected AUC0-∞ under co-dominant and dominant models.
Although the effect of ABCB1 and SLCO1B1 transporters on pharmacokinetics and pharmacodynamics, as 
well as on susceptibility to adverse effects has been well documented, there are few studies that assess the interac-
tion of these genes and their relationship with the effectiveness of treatment. Pharmacogenetics data from 1844 
subjects suggest that ABCB1 and SLCO1B1 variants may be useful for improving effectiveness and preventing 
the risks of adverse effects of statin treatment10. Our data on a Mexican population confirm that the transporters 
ABCB1 and SLCO1B1 have a significant impact on ATV metabolism (Fig. 1c,d). Although the SLCO1B1 trans-
porter had the greatest impact on ATV metabolism, the influence of ABCB1 is underscored by the fact that the 
presence of the ABCB1-rs1045642 C/C variant is sufficient to shift from an intermediate to a normal metabolism 
phenotype. Thus, different combinations of these two variants may generate a broad spectrum of metabolism and 
therefore a variable response to treatment. In our knowledge, this is the first study that demonstrates how the 
interaction of genetic variants affect metabolic phenotyping and improves understanding of how SLCO1B1 and 
ABCB1 variants that affect statin metabolism may explain the variability in drug response.
In the present study, some limitations remain. First, as only men were included in this study, our findings 
should be confirmed in women. Second, the lack of data on secondary metabolites of ATV did not allow us to val-
idate the metabolic classification by another method. Third, this study was limited to candidate polymorphisms. 
Thus, other polymorphisms or genes that could have an impact on the metabolism of ATV were not investigated.
Conclusions
Variants of the transporter-encoding genes ABCB1 and SLCO1B1 have an important impact on ATV pharma-
cokinetics in a Mexican male population. Hence, the metabolism also varies from population to population, even 
for the same drug. So, it is important that each study perform its metabolic classification. Our results improve the 
understanding of the mechanism by which variation in transporters may affect the therapeutic response to ATV 
in a Mexican population. ABCB1 and SLCO1B1 variants were not only congruent with, but could also explain, the 
metabolic phenotype classification at a genetic level.
Material and methods
Design. This pharmacogenetic study used pharmacokinetic data from a controlled, randomized, crossover, 
single-blind, three-treatment, three-period, and six-sequence clinical study after a single 80-mg oral dose of ATV 
(tablets; Pfizer Pharmaceuticals LLC, Caguas Site, Caguas, PR), conducted in 60 healthy Mexican men. The clini-
cal protocol complied with national and international ethical regulations, guidelines and norms, as described pre-
viously6, and was performed under medical supervision. The clinical protocol was approved by the Research and 
Ethics Committee of the Clinical and Experimental Pharmacology Center, Ipharma S. A. (Monterrey, NL, MEX), 
and registered at the Federal Commission for Protection Against Health Risks (COFEPRIS code: Atorvastatina/
A95-10Bis) and the Australian New Zealand Clinical Trials Registry (ACTRN12614000851662, registration date: 
08/08/2014). The pharmacogenetic procedure was approved by the Ethics, Research and Biosecurity Committees 
of the University of Monterrey (San Pedro Garza Garcia, NL, MEX; registry number 042014-CIE). Volunteers 
provided a written informed consent.
Study population. Between January and February 2011, sixty healthy, 18-to-45-year-old, non-smoking, 
Mexican males with a weight ≥ 50 kg and a body mass index between 20 and 26 kg/m2 participated in the bioe-
quivalence study. Their health status was assessed based on physical examination, medical history, and clinical 
and biochemical tests. Exclusion criteria included abnormal laboratory results, drug abuse, ingestion of alcohol 
1 week prior to the study, the use of medication three weeks before enrollment, and participation in a clinical 
research study within the previous 3 months.
Dosing regimen and sampling. The dosing and sampling involved a three-treatment (R = reference drug, 
T1 = Test 1 and T2 = Test 2 drugs are first and second treatment, respectively), three-period, and six-sequence 
schedule with a 2-week washout period between treatments. Before starting any drug administration, the statis-
tical department of Ipharma S.A. randomized drug allocation (R, T1 or T2, file code, and subject code) with a 
balanced design using the Mersenne Twister algorithm and R statistical software. The participants were blinded 
to treatment. About 18 h before the first dose administration, the subjects were admitted to the clinical site and 
served a standard dinner (<800 kcal). The next morning, after an overnight fast, ATV was administered orally as 
a single 80-mg dose tablet (Pfizer, New York, NY, USA) with 240 mL of water. A standardized lunch was served 
4 h after dosing and standardized dinner at 12 h after dosing. Peripheral blood (4-mL samples) was collected in 
K2EDTA-coated Vacutainers (BD Diagnostics, Franklin Lakes, NJ, USA), a pre-dose sample was taken (time 0), 
while other samples were taken at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 h after drug admin-
istration. Cells and plasma were separated (10 min at 1600 × g at 4 °C). Plasma was stored at −65 ± 15 °C until use 
while DNA was extracted from cells.
Plasma ATV quantitation. Proteins were eliminated by acetonitrile precipitation. Briefly, 400 µL acetoni-
trile was added to a 100-µL plasma sample, vortexed (70 rpm, 4 min), and centrifuged (9600 × g, 10 min, 10 °C). 
The supernatant (300 µL) was injected into a high-performance liquid chromatography-tandem mass spectrom-
etry equipped with an Agilent 1100 control system (Agilent Technologies, Inc., Santa Clara, CA, USA) using 
a method validated by Ipharma S.A6. that respects Mexican regulations54 and guidelines for the validation of 
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bioanalytical methods of the European Medicines Agency (EMA)55. An electrospray ionization tandem mass 
spectrometry system with a precursor ion (+) 559.3 m/z and a product ion (+) 440.3 m/z was used for detection. 
The linearity of the analytical method was assessed with calibration curves (0.5, 2.5, 5, 10, 25, 50 and 100 ng/mL), 
which yielded a correlation coefficient (r) = 0.99292 and a lower limit of quantification (LLOQ) = 0.5 ng/mL of 
ATV in plasma. Precision was assessed with control samples (1.7, 7.5, 35, and 75 ng/mL) and was considered 
within an acceptable range: intraday CV < 5% and interday CV < 8%. An accuracy error ≤7% was considered to 
be acceptable. The recovery was 87% and no effects were detected for the matrix, hemolyzed, and lipemic plasma 
(CV < 4%).
Pharmacokinetic analysis. The Cmax and time to reach Cmax (Tmax) were obtained from the 
concentration-time data. The pharmacokinetics parameters were determined by non-compartmental methods. 
The AUC0-t and AUC0-∞ were calculated with the log-linear trapezoidal rule. The Ke was estimated via log-linear 
regression from the terminal portion of the log-transformed concentration-time plots. T1/2 was estimated by 
dividing 0.693 by Ke. The Cl was calculated by dividing the dose by AUC0-∞ and adjusting for weight. The Vd was 
calculated as Cl divided by Ke. The AUC’s and Cmax values were adjusted for dose and weight (AUC’s/dW and 
Cmax/dW)17,56. The pharmacokinetic analysis was performed using WinNonlin software v5.3 (Pharsight Corp., 
Mountain View, CA, USA).
Determination of ATV metabolizer phenotypes. To estimate the ideal number of phenotypes, we 
applied a modified four-step multivariate analysis of the combined dose-and-weight-adjusted pharmacokinetic 
parameters Cmax, AUC0-t, AUC0-∞ and Cl6,14,16,57. First, hierarchical cluster analysis (HCA) was performed with 
the Ward linkage method and the distance matrix was calculated with the Manhattan measure. These analyses 
were applied to z-score transformed pharmacokinetic values to circumvent the comparability problems caused 
by the different scales of the non-transformed pharmacokinetic values. Aforementioned analysis were carried out 
with Minitab 16 software (Minitab Inc., State College, PA, USA). Second, we identified the subjects in each cluster, 
calculated the means of the adjusted pharmacokinetic parameters, and assigned the clusters to metabolizer phe-
notypes based on the means of the pharmacokinetic parameters. Third, we validated the phenotyping model by 
automatic linear modeling with the forward stepwise method, the Akaike Information Criterion (AICC) and the 
Overfit Prevention Criterion (ASE); followed by linear and logistic regression analysis. Finally, the cut-off limits 
were assessed by one-way analysis of variance and the Kruskal-Wallis test, considering P < 0.05 to be statistically 
significant different, with SPSS for Windows V.25 (IBM Corp., NY, USA).
Genotyping tests. Genomic DNA that had been isolated with the alkaline lysis method58 was quantified 
by fluorometry using the Qubit dsDNA BR assay kit and a Qubit 3.0 fluorometer (Invitrogen; Thermo Fisher 
Scientific, Waltham, MA, USA). Compliance with DNA purity (OD260/OD280 between 1.8 and 2) was assessed 
with a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). DNA was stored at 
10 ng/µL at −20 °C until analysis.
The polymorphisms ABCB1-rs1045642, SLCO1B1-rs4149056, CYP2B6-rs3745274, CYP2D6-rs16947, 
CYP2D6-rs1135840, NAT2-rs1208 and COMT-rs4680 were genotyped using a QuantStudio 1 real-time PCR 
system and TaqMan genotyping assays (Applied Biosystems; Thermo Fisher Scientific, Wilmington, MA, USA) 
according to the manufacturer’s protocol. Briefly, the PCR was prepared with 1X TaqMan Universal PCR Master 
Mix (Thermo Fisher Scientific, Inc.), 1X TaqMan genotyping assay mix, 10 ng DNA, and nuclease-free water to 
a total volume of 10 µl. Thermal cycling conditions were as follows: 95 °C for 10 min, 40 cycles of 95 °C for 15 sec 
and 60 °C for 1 min. Quality controls included a genotyping control using previously genotyped samples across 
different platforms, genotype call rate equal to 1.0, a Hardy-Weinberg equilibrium test with P > 0.05, and a minor 
allele frequency> 0.01. To detect the combination of the most important variants in the study population, a 
haplotype analysis was performed using the Haplotype Analysis Software V.1.0559, under a modified data entry 
method for diploid genomes.
Statistical analysis. The sample size calculation considered an intrasubject coefficient of variation (CV) of 
45% for Cmax and AUC, a confidence interval (CI) of 90%, a significance level of 5%, a minimum power of 80%, 
and a Ω of 0.25. Thus, a sample size of 58 would suffice. The Hardy-Weinberg equilibrium was determined by 
comparing the genotype frequencies with the expected values using the maximum likelihood method60. To assess 
the effects of polymorphisms on the ATV pharmacokinetic parameters, comparisons between two and three 
groups were made. The Student’s t-test and one-way analysis of variance were used for parametric distributions, 
while Mann-Whitney U and Kruskal-Wallis H tests were used for nonparametric distributions. Post hoc tests 
(Bonferroni’s and Tamhane’s T2) were used for pairwise comparisons. To confirm the contribution of genetic 
factors to the variability of pharmacokinetic parameters, automatic linear modeling with the forward stepwise 
method, AICC and ASE was performed, as well as linear regression analysis with various modes (default mode, 
stepwise, remove, backward and forward). Possible associations of genotypes or combinations of genotypes with 
phenotypes were evaluated using X2 and Fisher’s exact tests and validated by logistic regression analysis. The 
evaluation effect of polymorphisms and associations were assessed under four different models (co-dominant, 
dominant, over-dominant and recessive). The odds ratio (OR) was estimated with a 95% CI. All P values were 
two-tailed. Corrected P values (Pc) were obtained using the Bonferroni correction for exclusion of spurious asso-
ciations. P < 0.05 was interpreted as statistically significant. The statistical analyses were performed with SPSS for 
Windows, V.25 (IBM Corp., NY, USA).
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